15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 0.6% per year over the past 5 years.
Net income has grown slower than revenue (-25.4% vs 0.6% per year).
Operating margin has contracted, at 16.4% in the latest year.
Free cash flow has declined 15.5% per year over the past 5 years.
Financial health
Total debt ($75M) exceeds cash ($4M); net debt is $71M.
Total debt has grown faster than revenue (19.6% vs 0.6% per year).
Operating income covered interest expense 4.7× in the latest year.
Total debt is 2.5× EBITDA.
Shareholder returns
Dividends have been paid for 11 consecutive years, consuming 94.6% of earnings and 69.7% of free cash flow.
The dividend has grown 0.9% per year over the past 5 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$137M
$12M
0.0%
16.4%
$16M
$75M
$4M
2024
$143M
$25M
0.0%
24.6%
$19M
$58M
$4M
2023
$149M
$31M
0.0%
27.0%
$22M
$37M
$7M
2022
$152M
$32M
0.0%
30.7%
$26M
$22M
$25M
2021
$148M
$37M
0.0%
34.0%
$41M
$27M
$54M
2020
$133M
—
0.0%
32.0%
$37M
$31M
$35M
2019
$128M
—
0.0%
33.6%
$36M
$34M
$14M
2018
$120M
$30M
0.0%
29.5%
$34M
$38M
$13M
2017
$118M
$23M
0.0%
29.1%
$24M
$1M
$35M
2016
—
$21M
—
—
$23M
$4M
$33M
2015
—
$18M
—
—
$19M
$6M
$42M
2014
—
$18M
—
—
$24M
$8M
$40M
2013
—
$15M
—
—
$17M
$10M
$22M
2012
—
$15M
—
—
$17M
$12M
$8M
2011
—
$12M
—
—
$16M
$14M
$8M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$35M
$3M
0.0%
16.0%
$5M
$74M
$3M
Dec '25
$35M
$2M
0.0%
13.3%
$6M
$75M
$4M
Sep '25
$35M
$4M
0.0%
22.4%
$10M
$76M
$2M
Jun '25
$34M
-$106000
0.0%
4.7%
-$4M
$77M
$5M
Mar '25
$34M
$6M
0.0%
25.6%
$4M
$59M
$3M
Dec '24
$37M
$7M
0.0%
26.0%
$2M
$58M
$4M
Sep '24
$36M
$6M
0.0%
22.3%
$8M
$49M
$3M
Jun '24
$35M
$6M
0.0%
25.3%
$2M
$33M
$485000
Mar '24
$35M
$6M
0.0%
24.8%
$8M
$35M
$2M
Dec '23
$38M
$9M
0.0%
30.8%
$8M
$37M
$7M
Sep '23
$38M
$8M
0.0%
26.2%
$5M
$19M
$4M
Jun '23
$36M
$7M
0.0%
25.9%
$4M
$20M
$22M
Mar '23
$36M
$7M
0.0%
24.7%
$5M
$21M
$24M
Dec '22
$38M
$7M
0.0%
32.1%
$6M
$22M
$25M
Sep '22
$38M
$8M
0.0%
29.5%
$6M
$23M
$28M
Jun '22
$37M
$8M
0.0%
30.8%
$8M
$24M
$33M
Mar '22
$38M
$9M
0.0%
30.4%
$6M
$26M
$47M
Dec '21
$38M
$10M
0.0%
33.6%
$10M
$27M
$54M
Sep '21
$38M
$10M
0.0%
34.8%
$8M
$28M
$52M
Jun '21
$36M
$9M
0.0%
33.6%
$10M
$29M
$49M
Valuation over time
How the market has priced NRC against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has risen from 30.8× (Mar '23) to 39.9× (Jun '26).
The price-to-sales ratio has fallen from 6.5× (Mar '23) to 3.4× (Jun '26).
The dividend yield has risen from 2.1% (Mar '23) to 2.4% (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is NRC growing its revenue and profit?
Over the past 5 years, Nrc Health's revenue has grown 0.6% per year, and net income declined 25.4% per year. These are computed facts, not advice.
How much debt does NRC have?
As of FY2025, Nrc Health reported $75M of total debt against $4M of cash; operating income covered interest expense 4.7×.
What is NRC's profit margin?
In FY2025, gross margin was —, operating margin 16.4%, and net margin 8.4%.
What is NRC's P/E ratio?
As of Jun '26, Nrc Health traded at a price-to-earnings ratio of about 39.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.